Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation

Detalles Bibliográficos
Autores principales: Chen, Si-Si, Sun, Qian, Cao, Lan, Wu, Wen-Zhong, Xie, Yue, Qiao, Chun, Li, Jian-Yong, Qian, Si-Xuan, Hong, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Clinical Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213253/
https://www.ncbi.nlm.nih.gov/pubmed/33323826
http://dx.doi.org/10.1097/CM9.0000000000001316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213253/
https://www.ncbi.nlm.nih.gov/pubmed/33323826
http://dx.doi.org/10.1097/CM9.0000000000001316

Ejemplares similares